EUVIMEDEUVIMED entdecken
Kohortenstudie

Systemic treatment-free period following dupilumab discontinuation for atopic dermatitis: A nationwide cohort study

Marion Gundelwein iD, Delphine Staumont-Sallé iD, Sandrine Kerbrat, Lucie-Marie Scailteux, Catherine Droitcourt iD

Clinical and Experimental Dermatology · 13.11.2026

DOI: 10.1093/ced/llag467 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 13.11.2026. Verfasst von Marion Gundelwein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is limited data regarding discontinuation of dupilumab in atopic dermatitis (AD). This study aimed to determine the proportion of patients with a systemic treatment-free period of ≥12 months following dupilumab discontinuation, and to describe patient characteristics and care trajectories. We conducted a cohort study including 7,214 patients with severe AD treated with dupilumab for ≥6 months. Overall, 900 patients (12%) discontinued dupilumab for ≥12 months, without switching to another systemic treatment. Within this group, 72% remained off-systemic treatment throughout the follow-up, 22% restarted treatment with dupilumab and 6% switched to another systemic treatment. Patients who did not receive further systemic treatment tended to be older and, in the year following discontinuation, required fewer topical corticosteroids and fewer dermatologist consultations compared to patients who restarted systemic treatment. In conclusion, among patients who discontinued dupilumab for ≥12 months, most did not receive further systemic treatment throughout follow-up, suggesting that a systemic treatment-free period may be achievable in AD.

Autor:innen und Institutionen

  • Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.
  • Department of Dermatology, University Hospital of Lille, INFINITE (Institute for Translational Research) U1286 Inserm, University of Lille, Lille, France.
  • Damad, Plouzané, France.
  • Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Department of Clinical Pharmacology, Rennes Hospital, France.
  • Department of Dermatology, Univ Rennes, CHU Rennes, Rennes, France.

ORCID-Profile: Marion Gundelwein, Delphine Staumont-Sallé, Catherine Droitcourt

Zitieren

APA

Gundelwein, M., Staumont-Sallé, D., Kerbrat, S., Scailteux, L. M., & Droitcourt, C. (2026). Systemic treatment-free period following dupilumab discontinuation for atopic dermatitis: A nationwide cohort study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag467

Vancouver

Gundelwein M, Staumont-Sallé D, Kerbrat S, Scailteux LM, Droitcourt C. Systemic treatment-free period following dupilumab discontinuation for atopic dermatitis: A nationwide cohort study. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag467

BibTeX
@article{Gundelwein2026,
  author = {Gundelwein, Marion and Staumont-Sallé, Delphine and Kerbrat, Sandrine and Scailteux, Lucie-Marie and Droitcourt, Catherine},
  title = {Systemic treatment-free period following dupilumab discontinuation for atopic dermatitis: A nationwide cohort study},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  doi = {10.1093/ced/llag467}
}
Kostenlos starten →